Desmethylmoramide

Sumamry

Desmethylmoramide, known by its INN (International Nonproprietary Name), is an opioid analgesic with a connection to dextromoramide, the active (+)-isomer of moramide. It was synthesized and characterized during the late 1950s but did not enter the market.

Identifiers
CAS Number1767-88-0 
3D model (JSmol)Interactive image
ChEMBLChEMBL2106152
ChemSpider178501
PubChemCID206005
UNII9B1Z1V29C3 
CompTox Dashboard(EPA)DTXSID60170172

FAQ

  • What is Desmethylmoramide?
  • Desmethylmoramide is an opioid analgesic that is related to dextromoramide, the active (+)-isomer of moramide. It was synthesized and characterized in the late 1950s but was never commercially marketed.
  • What is the purpose of Desmethylmoramide?
  • Desmethylmoramide was developed as an analgesic, which means it was intended for use in managing pain, similar to other opioids.
  • Why was Desmethylmoramide not marketed?
  • While Desmethylmoramide was synthesized and characterized, it did not make it to the market. The reasons for this non-commercialization could include factors such as safety concerns, efficacy issues, or market conditions at the time.
  • Is Desmethylmoramide available for medical use today?
  • No, Desmethylmoramide is not currently available for medical use, and it is not a commonly prescribed or used medication.
  • What are the potential risks and side effects of Desmethylmoramide?
  • Since Desmethylmoramide is not in everyday use, its specific side effects and risks are not well-documented. However, as an opioid analgesic, it could potentially have side effects similar to other opioids, such as drowsiness, constipation, and, in high doses, the risk of respiratory depression.
  • Is Desmethylmoramide a controlled substance?
  • The legal status of Desmethylmoramide may vary by country. In many places, opioids are regulated as controlled substances due to their potential for abuse and addiction.
  • Is Desmethylmoramide related to the opioid crisis?
  • While Desmethylmoramide itself is not widely known to have contributed to the opioid crisis, the opioid crisis is primarily associated with the abuse and misuse of other opioids, such as prescription painkillers and illegal opioids like heroin and fentanyl.
  • Can a doctor prescribe Desmethylmoramide today?
  • In most countries, Desmethylmoramide is not an approved or commonly prescribed medication. Medical professionals have more modern and effective opioid and non-opioid pain management options available.
  • Is Desmethylmoramide available on the black market?
  • Since Desmethylmoramide was not commercially marketed and is not a commonly known substance, it is unlikely to be readily available on the black market.
  • Is there ongoing research or interest in Desmethylmoramide?
  • Given the limited information available and the lack of market availability, Desmethylmoramide is not a focus of current research or medical interest. More modern opioid medications and pain management strategies have taken precedence.

References

  1. Elks, J. (November 14, 2014). “The Compendium of Pharmaceuticals: Chemical Insights, Structures, and Citations.” Published by Springer, this authoritative reference work spans 363 pages. It is identified by the ISBN 978-1-4757-2085-3.
  2. Morton, I.K., and Hall, J.M. (December 6, 2012). “A Compact Lexicon of Pharmacological Substances: Characteristics and Synonyms.” Published by Springer Science & Business Media, this concise guide comprises 94 pages. It is recognized by the ISBN 978-94-011-4439-1.
  3. In June 1957, Janssen, P.A., and Jageneau, A.H. unveiled “A Novel Line of Potent Analgesics: Dextro 2:2-Diphenyl-3-Methyl-4-Morpholino-Butyrylpyrrolidine and Allied Amides. Part I: Chemical Structure and Pharmacological Effects” in “The Journal of Pharmacy and Pharmacology.” This research article, in volume 9, issue 6, spans pages 381 to 400. It is available under the DOI: 10.1111/j.2042-7158.1957.tb12290.x, with the PMID 13439527 and S2CID 58956931.

Leave a Comment

Your email address will not be published. Required fields are marked *